t
Physiomics plc Director Ian Bagnall acquired 1,111,111 new ordinary shares at 0.45p per share via market purchases on the London Stock Exchange on 10 July 2026. Following this transaction, Mr. Bagnall's total holding is 16,111,111 Ordinary Shares, representing approximately 3.55% of the Company's issued share capital.
| Date | 14 Jul 2026 |
| Time | 07:00:05 |
| Category | Director/PDMR dealings |
| ID | 1690M |
14 July 2026
Physiomics plc
("Physiomics" or the "Company")
Director Dealing
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the Company, has acquired, via market purchases, 1,111,111 new ordinary shares of 0.4p in the Company ("Ordinary Shares") at a price of 0.45p per Ordinary Share.
Accordingly, Mr Bagnall's total holding in the Company will be 16,111,111 Ordinary Shares, representing approximately 3.55% of the Company's issued share capital.
ENDS
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Enquiries:
|
Physiomics plc Mike Whitlow
|
Email: [email protected] |
|
Strand Hanson Ltd (NOMAD and Broker) James Dance & James Bellman |
Tel: +44 (0) 20 7409 3494
|
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
PDMR Notification Form:
The notification below, which has been made in accordance with the requirements of UK MAR, provides further details.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Ian Bagnall |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Executive Director |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Physiomics plc |
||||
|
b) |
LEI |
213800A71DSZ6ABMTQ91 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Purchase of Ordinary Shares |
||||
|
Identification code |
GB00BDR6W943 |
|||||
|
b) |
Nature of the Transaction |
Purchase of new Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (Single transaction) |
||||
|
e) |
Date of the transaction |
10 July 2026 |
||||
|
f) |
Place of the transaction |
London Stock Exchange |
||||